Inotiv (NOTV) and Vugene, a multi-omics data analysis company providing advanced artificial intelligence and machine learning solutions for biomedical research, announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum. Inotiv will integrate Vugene’s cloud-based bioinformatics and computational platform into its Discovery & Translational Sciences Division.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOTV:
- Inotiv, Inc. Faces Business Risks Amid FDA Disruptions and Government Funding Challenges
- Inotiv, Inc. Earnings Call: Growth Amid Challenges
- Inotiv price target lowered to $3 from $5 at Lake Street
- Inotiv, Inc. Reports Improved Fiscal 2025 Results
- NOTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?